Skip to main
ABSI
ABSI logo

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci Corp's positive outlook is supported by its strong assumptions regarding the clinical activity of ABS-101, which could potentially increase the probability of success (POS) in ulcerative colitis (UC) and Crohn's disease (CD) to 15%. A favorable outcome in clinical trials could validate Absci's comprehensive platform and attract interest from large pharmaceutical companies, showcasing its potential for significant advancements in biologic drug development. Additionally, the ongoing collaboration expansion with Almirall illustrates Absci's capability in delivering innovative therapeutics and underscores its guidance of securing at least one partnership with large pharma by 2025.

Bears say

The financial analysis indicates a negative outlook on Absci Corp's stock primarily due to increased dilution resulting from a recent financing round, which has pressured the company's valuation. Additionally, the lack of standard of care (SOC) in the endometriosis treatment segment, particularly for non-hormonal options, further raises concerns about the company's market positioning and potential revenue generation. Overall, these factors contribute to a cautious assessment of Absci's financial stability and growth prospects.

Absci Corp (ABSI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.